Rhythm Pharmaceuticals, Inc. (BMV:RYTM)
Mexico · Delayed Price · Currency is MXN | Market Cap | 107.27B +33.1% |
| Revenue (ttm) | 3.91B +58.7% |
| Net Income | -3.75B |
| EPS | -56.59 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 599 |
| Average Volume | 3,380 |
| Open | 1,866.76 |
| Previous Close | 2,025.00 |
| Day's Range | 1,866.76 - 1,866.76 |
| 52-Week Range | 1,800.00 - 2,025.00 |
| Beta | n/a |
| RSI | 78.94 |
| Earnings Date | Aug 4, 2026 |
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic... [Read more]
Financial Performance
In 2025, Rhythm Pharmaceuticals's revenue was $189.76 million, an increase of 45.83% compared to the previous year's $130.13 million. Losses were -$201.92 million, -23.68% less than in 2024.
Financial numbers in USD Financial StatementsNews
Rhythm Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
The company’s drug targets rare genetic and acquired obesity syndromes, with a recent HO launch showing strong early uptake and broad physician engagement. Next-generation therapies aim to improve convenience and reduce side effects, while ongoing studies in Prader-Willi syndrome may expand indications.
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with acquired hypothalamic obesity (HO) in France –
Rhythm Pharmaceuticals price target raised to $143 from $140 at Canaccord
Canaccord raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $143 from $140 and keeps a Buy rating on the shares. The firm said the company delivered a topline…
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...
Rhythm Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw $60.1M in revenue, driven by BBS and a strong U.S. launch of IMCIVREE for acquired HO, with over 150 start forms and positive payer response. International expansion advanced with EU approval and Japan NDA filing, supporting a robust outlook for 2026.
Rhythm Pharmaceuticals Earnings release: Q1 2026
Rhythm Pharmaceuticals released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Rhythm Pharmaceuticals Slides: Q1 2026
Rhythm Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Rhythm Pharmaceuticals Quarterly report: Q1 2026
Rhythm Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 5, 2026.
Rhythm Pharmaceuticals Proxy statement: Proxy filing
Rhythm Pharmaceuticals filed a proxy statement on May 5, 2026, providing details for shareholder voting and corporate governance matters.
Rhythm Pharmaceuticals reports Q1 EPS (83c), consensus (86c)
Reports Q1 revenue $60.11M, consensus $56.07M. “The U.S and European approvals of IMCIVREE mark a transformational milestone for patients with acquired hypothalamic obesity who, until now, had no appr...
Rhythm Pharmaceuticals sees FY26 operating expenses $385M-$415M
Meeker added, “In addition, we continue to advance our MC4R agonism pipeline with upcoming data readouts from ongoing trials of setmelanotide in Prader-Willi syndrome and our weekly injectable, RM-718...
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
-- IMCIVREE ® (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026 -- -- F...
Rhythm Pharmaceuticals presents Phase 3 TRANSCEND trial data
Rhythm Pharmaceuticals (RYTM) announced the presentation of new data delivered by Rhythm and its partners at The Pediatric Endocrine Society Annual Meeting. “The data presented provide important longe...
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
-- Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z at 2.5 years of setmelanotide therapy -- -- Weight category improvements observed in pedi...
Rhythm Pharmaceuticals’ Imcivree granted MAA in Europe for obesity
Rhythm Pharmaceuticals (RYTM) announced the European Commission, or EC, has expanded the marketing authorization for Imcivree – setmelanotide – to include the treatment of obesity and control of hunge...
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
-- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity -- -- European Commission grants authorization in adults and children 4 years of age and above with acquired hyp...
Rhythm Pharmaceuticals Proxy statement: Proxy filing
Rhythm Pharmaceuticals filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Rhythm Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
IMCIVREE’s U.S. launch for acquired HO is underway, with expansion planned in Europe and Japan. Key pipeline updates include mid-year PWS data and phase III studies for new agents. The company is focused on rare MC4R pathway diseases, with strong cash reserves and a long-term vision for global leadership.
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
BOSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra...
Rhythm Pharmaceuticals price target raised to $136 from $130 at RBC Capital
RBC Capital raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $136 from $130 and keeps an Outperform rating on the shares as part of the firm’s broader research…
Rhythm Pharmaceuticals Slides: Corporate presentation
Rhythm Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on April 7, 2026.
Rhythm Pharmaceuticals appoints Popovits to board of directors
Rhythm Pharmaceuticals (RYTM) announced changes to its Board of Directors, including the appointment of Kim Popovits and the departure of Ed Mathers. Popovits previously served as Chairman of the Boar...
Rhythm Pharmaceuticals Announces Changes to Board of Directors
-- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical c...
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
-- European Commission decision anticipated in second quarter of 2026 -- BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceut...
Rhythm Pharmaceuticals price target raised to $105 from $100 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $105 from $100 and keeps a Buy rating on the shares after the FDA approved…